Uniform field controlled magnetic cell targeting to stents
Uniform field controlled magnetic cell targeting to stents
批准号:
9024605
负责人:
Michael Chorny
金额:
$41.88万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-04-16 至 2019-02-28
关键词:
AddressAdverse effectsAftercareAngioplastyAnimalsArterial InjuryArteriesAutologousBiological AssayBioluminescenceBlood VesselsCarotid stentCell LineCell ProliferationCell SurvivalCellsCharacteristicsCultured CellsDoseDrug or chemical Tissue DistributionEndothelial CellsEnergy TransferFamily suidaeFirefly LuciferasesFormulationGenerationsGrowthHealedHomingImageIn VitroKineticsLabelLuciferasesMagnetic nanoparticlesMagnetismMeasurementMeasuresMediatingMethodologyMethodsModelingModificationPatientsPolymersPrecipitationProceduresProcessPropertyPublicationsRattusReporterResearchSchemeSiteStenosisStentsTechniquesTherapeuticTherapeutic EffectToxic effectVascular Diseasesbasebiomaterial compatibilitycomputerizedhealingimplantationin vivoin vivo Modelinjuredinnovationluminescencemorphometrynovelparticlephysical propertypreventprogramsrepairedresearch studyrestenosistargeted deliveryuptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The proposed research will explore the hypothesis that magnetically guided targeting of endothelial cells (EC) to stented arteries can reduce vessel reocclusion (restenosis) following stent angioplasty. Re-endothelialization oriented strategies have potential to prevent restenosis while avoiding the side effects of the currently used therapies. However, in order to fully realize this potential a significant improvement in cell delivery efficiency is required. This study will investigate two novel ideas: 1) the application of
magnetic nanoparticles (MNP) for providing EC with magnetic responsiveness adequate for their targeted delivery to stented arteries; and 2) using a uniform field-controlled magnetic targeting of EC to reversibly magnetizable stents for enhanced reendothelialization and inhibition of restenosis post stenting. The present studies will address the following specific aims: AIM 1: MNP characterization with respect to their physical properties, cell compatibility, uptake and degradation kinetics. Biodegradable fluorescent-labeled MNP will be formulated using a modification of the polymer precipitation approach. The size, composition and magnetic properties of MNP will be characterized, and their cell compatibility, internalization and degradation kinetics will be the main endpoints of the Aim 1 experiments. The magnetic responsiveness of MNP and EC treated with MNP will be measured by alternating gradient magnetometer. The kinetic studies will be performed in cultured cells using fluorimetry and global FQrster Resonance Energy Transfer measurements. Cell compatibility of MNP will be determined using fluorimetric cell toxicity assays. AIM 2: EC targeting and reendothelialization studies. Arterial localization and tissue distribution after magnetic vs. non- magnetic delivery of
MNP-impregnated EC stably expressing firefly luciferase will be studied by in vivo bioluminescence and luminometry, respectively, in the rat carotid stenting model. The local kinetic profiles of stent-targeted cells will be compared 1, 7 and 28 days post treatment with endothelialization determined using a quantitative immunohistochemical strategy. AIM 3: antirestenotic efficacy of targeted EC. The extent of restenosis in animals treated under magnetic conditions with MNP-loaded EC will be determined by computerized morphometry and compared that in non-magnetic delivery and 'stenting only' controls four weeks post delivery.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.jconrel.2015.12.025
发表时间:
2016-01-28
期刊:
Journal of controlled release : official journal of the Controlled Release Society
影响因子:
--
作者:
[Adamo RF, Fishbein I, Zhang K, Wen J, Levy RJ, Alferiev IS, Chorny M]
通讯作者:
Chorny M
DOI:
10.1038/gt.2017.82
发表时间:
2017-11
期刊:
Gene therapy
影响因子:
5.1
作者:
[Fishbein I, Guerrero DT, Alferiev IS, Foster JB, Minutolo NG, Chorny M, Monteys AM, Driesbaugh KH, Nagaswami C, Levy RJ]
通讯作者:
Levy RJ
Multimeric prodrugs for pulmonary hypertension therapy
-
批准号:10475200
-
项目类别:
-
资助金额:$26.4万
-
财政年份:2021
-
负责人:Michael Chorny
-
依托单位:
Multimeric prodrugs for pulmonary hypertension therapy
-
批准号:10287001
-
项目类别:
-
资助金额:$22.0万
-
财政年份:2021
-
负责人:Michael Chorny
-
依托单位:
Local Control of endochondral ossification by retinoid-loaded nano-particles
-
批准号:10238000
-
项目类别:
-
资助金额:$34.53万
-
财政年份:2018
-
负责人:Michael Chorny
-
依托单位:
Local Control of endochondral ossification by retinoid-loaded nano-particles
-
批准号:10472544
-
项目类别:
-
资助金额:$35.25万
-
财政年份:2018
-
负责人:Michael Chorny
-
依托单位:
Integrated drug-in-cell therapy of in-stent restenosis
-
批准号:9256528
-
项目类别:
-
资助金额:$25.2万
-
财政年份:2016
-
负责人:Michael Chorny
-
依托单位:
Uniform field controlled magnetic cell targeting to stents
-
批准号:8625329
-
项目类别:
-
资助金额:$41.04万
-
财政年份:2012
-
负责人:Michael Chorny
-
依托单位:
Uniform field controlled magnetic cell targeting to stents
-
批准号:8459382
-
项目类别:
-
资助金额:$39.87万
-
财政年份:2012
-
负责人:Michael Chorny
-
依托单位:
Uniform field controlled magnetic cell targeting to stents
-
批准号:8305243
-
项目类别:
-
资助金额:$41.88万
-
财政年份:2012
-
负责人:Michael Chorny
-
依托单位:
Uniform field controlled magnetic cell targeting to stents
-
批准号:8806592
-
项目类别:
-
资助金额:$41.25万
-
财政年份:2012
-
负责人:Michael Chorny
-
依托单位:
海外基金